Key result
Lingguizhugan decoction improves hemodynamics, cardiac structure, and survival in CHF rats while reducing NF-kappaB expression.
Why the study?
The effect of Lingguizhugan decoction on cardiac structure, function, and myocardial NF-kappaB expression in chronic heart failure was investigated to explore its mechanism of action.
Does Lingguizhugan decoction improve cardiac structure and function and reduce NF-kappaB expression in rats with chronic heart failure?
RCT
randomly classified
Does Lingguizhugan decoction improve cardiac structure and function and reduce NF-kappaB expression in rats with chronic heart failure?
Lingguizhugan decoction improves cardiac structure and function in a rat model of chronic heart failure, potentially via inhibition of NF-kappaB.
Hypothesis-generating in rodent HF; leaves open clinical translation and human trials of Lingguizhugan decoction.
OBJECTIVE: To investigate the effect of Lingguizhugan decoction (LGZGD) on changes of cardiac structure and function, and its putative mechanism of action, by investigating mRNA and protein expression of myocardial nuclear factor kappa B (NF-kappaB), and the plasma content of NF-kappaB in rats with chronic heart failure. METHODS: The chronic heart failure (CHF) model in rats was induced by coronary artery ligation. Sham operation was performed in control rats. Six weeks after the procedure, rats were randomly classified into the various treatment groups: model CHF, Captopril (4.4 mg/kg), low LGZGD dose (2.1 g/kg), medium LGZGD dose (4.2 g/kg), and high LGZGD dose (8.4 g/kg). Treatments continued for 4 consecutive weeks. Changes of hemodynamic indices were observed by the PowerLab data acquisition and analysis system. Morphological changes of myocardium were observed by hematoxylin and eosin staining, and Masson staining. The mRNA and protein expression of myocardial NF-kappaB were detected by reverse transcription-polymerase chain reaction and western blotting, respectively. The plasma content of NF-kappaB was detected by enzyme-linked immuno-sorbent assay. RESULTS: CHF rats showed significant dysfunction in hemodynamic indices and in cardiac structure. Compared with the sham operation group, mRNA expression of myocardial NF-kappaB and plasma content of NF-kappaB of the model group was significantly increased. All three doses of LGZGD, and Captopril, improved the hemodynamic dysfunction, and inhibited the change of cardiac structure while significantly improving the survival rate. Furthermore, compared with the model group, mRNA expression of myocardial NF-kappaB and plasma content of NF-kappaB were significantly reduced by all dosage groups of LGZGD as well as the Captopril group. CONCLUSION: In CHF rats, LGZGD improves changes of cardiac structure and function via its inhibition of NF-kappaB.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2013) conducted an RCT in chronic heart failure. Lingguizhugan decoction (LGZGD) vs. model CHF and Captopril was evaluated on hemodynamic indices, cardiac structure, survival rate, and NF-kappaB expression. In rats with chronic heart failure, Lingguizhugan decoction improved hemodynamic dysfunction, cardiac structure, and survival rate while reducing NF-kappaB expression.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: